ASAndré Steven

André Steven

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


André Steven has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara Seliger

    Martin Luther University Halle-Wittenberg

    8 shared publications
  • Sandra Leisz

    Department of Neurosurgery, Medical Faculty, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120 Halle (Saale), Germany

    4 shared publications
  • Bernhard Hiebl

    Institute for Animal Hygiene, Animal Welfare and Farm Animal Behavior, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany

    3 shared publications
  • Rolf Kiessling

    Karolinska Institutet, CCK, Stockholm, Sweden

    3 shared publications
  • Anja Müller

    Authors' Affiliations: Institutes of 1Medical Immunology and 2Pathology, 3Centre for Basic Medical Research, Martin Luther University Halle-Wittenberg, Halle, Germany; and 4Centre for Aging Research (CeSI), “G. D'Annunzio” University of Chieti–Pescara, Chieti, Italy

    2 shared publications
  • Chiara Massa

    Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

    2 shared publications

Latest Publications

  • Receptor activator of NFκB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma

    by A. Steven, N. Kroeger, S. Leisz, S. Fussek, B. Nowroozizadeh, J. Huang, D. Brandstetter, B. Dougall, M. Burchardt, A. Belldegrun, et al.

  • Top Cited Papers

    LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

    by Almut Brand, Katrin Singer, Gudrun E. Koehl, Marlene Kolitzus, Gabriele Schoenhammer, Annette Thiel, Carina Matos, Christina Bruss, Sebastian Klobuch, Katrin Peter, et al.


  • Open Access

    Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization

    by André Steven, Sandra Leisz, Katharina Sychra, Bernhard Hiebl, Claudia Wickenhauser, Dimitrios Mougiakakos, Rolf Kiessling, Carsten Denkert, Barbara Seliger

    Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization


  • Open Access

    Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target

    by André Steven, Barbara Seliger

    Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target


  • Colorectal Carcinogenesis: Connecting K-RAS–Induced Transformation and CREB Activity In Vitro and In Vivo

    by André Steven, Max Heiduk, Christian V. Recktenwald, Bernhard Hiebl, Claudia Wickenhauser, Chiara Massa, Barbara Seliger

    Oncogenic transformation is often associated with an increased expression of the cAMP response element binding (CREB) transcription factor controlling the expression of genes involved in cell proliferation, cell cycle, apoptosis, and tumor development, but a link between K-RASV12-induced transformation and CREB has not yet been determined. Therefore, the constitutive and/or inhibitor-regulated mRNA and protein expression of CREB and signal transduction components and growth properties of parental fibroblasts, K-RASV12-transformed counterparts, shCREB K-RASV12 transfectants and human colon carcinoma cells were determined. Increased CREB transcript and protein levels accompanied by an enhanced CREB activity was detected in K-RASV12-transformed murine fibroblasts and K-RASV12-mutated human tumor cells, which is dependent on the MAPK/MEK, PI3K, and/or PKC signal transduction. Immunohistochemical (IHC) staining of colorectal carcinoma lesions and murine tumors, with known KRAS gene mutation status, using antibodies specific for CREB and phospho-CREB, revealed a mechanistic link between CREB expression and K-RASV12-mutated colorectal carcinoma lesions when compared with control tissues. Silencing of CREB by shRNA and/or treatment with a CREB inhibitor (KG-501) reverted the neoplastic phenotype of K-RASV12 transformants as demonstrated by a more fibroblast-like morphology, enhanced apoptosis sensitivity, increased doubling time, decreased migration, invasion and anchorage-independent growth, reduced tumorigenesis, and enhanced immunogenicity in vivo. The impaired shCREB-mediated invasion of K-RASV12 transformants was accompanied by a transcriptional downregulation of different matrix metalloproteinases (MMP) coupled with their reduced enzymatic activity. Implications: CREB plays a key role in the K-RASV12-mediated neoplastic phenotype and represents a suitable therapeutic target for murine and human K-RASV12-induced tumors. Mol Cancer Res; 13(8); 1248–62. ©2015 AACR.


  • Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

    by Yumeng Mao, Dhifaf Sarhan, André Steven, Barbara Seliger, Rolf Kiessling, Andreas Lundqvist

    Purpose: Increased frequencies of myeloid-derived suppressor cells (MDSC) correlate with poor prognosis in patients with cancers. Tumor-derived prostaglandin-E2 (PGE2) plays an important role in inducing MDSCs. However, the detailed mechanisms of this induction remain unknown. To develop targeted therapies for MDSCs, we sought to investigate the molecular basis of PGE2-regulated accumulation of MDSCs and their functional consequence on natural killer (NK) cell activity. Experimental Design: The effects of PGE2 in inducing phenotypic, signaling, and functional alternations on monocytes were analyzed in vitro. Suppression of NK-cell activity by PGE2-treated monocytes was compared with that of freshly isolated CD14+HLA-DRlow/− monocytic MDSCs (moMDSC) from patients with melanoma. In addition, to explore the in vivo relevance of targeting PGE2 to reduce MDSC-mediated suppression of NK cells, we established a murine model, where tumor cells were disabled from cyclooxygenase-2 (COX-2) production. Results: Patient-derived moMDSCs inhibited NK-cell activity through the production of TGFβ. In vitro, binding of PGE2 to EP2 and EP4 receptors on monocytes activated the p38MAPK/ERK pathway and resulted in elevated secretion of TGFβ. Similar to moMDSCs, PGE2-treated monocytes potently suppressed NK-cell activity through production of TGFβ. Furthermore, silencing COX-2 in murine 4T1 tumor cells reduced the accumulation of CD11b+Gr1+ MDSCs in the spleen, resulting in concomitant improved in vivo clearance of NK-cell sensitive YAC-1 cells. Conclusions: Our results reveal an indispensable role of tumor-derived PGE2 in inducing MDSCs and suggest a favorable outcome of combining COX-2–targeted therapy and adoptive NK-cell transfer in patients with cancer. Clin Cancer Res; 20(15); 4096–106. ©2014 AACR.


  • HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function

    by André Steven, Sandra Leisz, Chiara Massa, Manuela Iezzi, Rossano Lattanzio, Alessia Lamolinara, Jürgen Bukur, Anja Müller, Bernhard Hiebl, Hans-Jürgen Holzhausen, et al.

    The cyclic (c)AMP responsive element binding protein (CREB) plays a key role in many cellular processes, including differentiation, proliferation, and signal transduction. Furthermore, CREB overexpression was found in tumors of distinct origin and evidence suggests an association with tumorigenicity. To establish a mechanistic link between HER-2/neu–mediated transformation and CREB protein expression and function, in vitro models of HER-2/neu–overexpressing and HER-2/neu–negative/silenced counterparts as well as human mammary carcinoma lesions with defined HER-2/neu status were used. HER-2/neu overexpression resulted in the induction and activation of CREB protein in vitro and in vivo, whereas short hairpin RNA (shRNA)–mediated inhibition of HER-2/neu correlated with downregulated CREB activity. CREB activation in HER-2/neu–transformed cells enhanced distinct signal transduction pathways, whereas their inhibition negatively interfered with CREB expression and/or activation. CREB downregulation in HER-2/neu–transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G0–G1 cell-cycle arrest, which was rescued by CREB expression. This was accompanied by reduced cell migration, wound healing, an increased fibronectin adherence, invasion, and matrix metalloproteinase expression. In vivo shCREB-HER-2/neu+ cells, but not control cells, exerted a significantly decreased tumorgenicity that was associated with decreased proliferative capacity, enhanced apoptosis, and increased frequency of T lymphocytes in peripheral blood mononuclear cells. Thus, CREB plays an important role in the HER-2/neu–mediated transformation by altering in vitro and in vivo growth characteristics.


  • Open Access

    HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties

    by Christian V. Recktenwald, Sandra Leisz, André Steven, Kousaku Mimura, Anja Müller, Jens Wulfänger, Rolf Kiessling, Barbara Seliger